Research graph
References from THE INNOVATIVE MEDICINES INITIATIVE: A PUBLIC PRIVATE PARTNERSHIP MODEL TO FOSTER DRUG DISCOVERY. Local targets link to admitted publications; unresolved targets remain external evidence.
Lessons from 60 years of pharmaceutical innovation
10.1038/nrd2961 · 2009 · External reference
Unresolved reference
External reference
From sick care to health care—reengineering prevention into the U.S. system
10.1056/nejmp1206230 · 2012 · External reference
10.1038/nrd1470
10.1038/nrd1470 · External reference
How to improve R&D productivity: the pharmaceutical industry's grand challenge
10.1038/nrd3078 · 2010 · External reference
Requirements for a lead compound to become a clinical candidate
10.1186/1471-2202-9-s3-s7 · 2008 · External reference
Towards new business models for R&D for novel antibiotics
10.1016/j.drup.2011.01.006 · 2011 · External reference
Innovative solutions to novel drug development in mental health
10.1016/j.neubiorev.2013.03.022 · 2013 · External reference
10.1126/scitranslmed.3001137
10.1126/scitranslmed.3001137 · External reference
Improving R&D productivity of pharmaceutical companies through public–private partnership: experiences from the Innovative Medicines Initiative
10.1586/erp.12.59 · 2012 · External reference
10.1038/clpt.2009.51
10.1038/clpt.2009.51 · External reference
10.1016/j.drudis.2012.05.007
10.1016/j.drudis.2012.05.007 · External reference
Public-private partnerships as driving forces in the quest for innovative medicines
10.1186/2001-1326-2-2 · 2013 · External reference
The FDA critical path initiative and its influence on new drug development
10.1146/annurev.med.59.090506.155819 · 2008 · External reference
10.1038/npp.2008.125
10.1038/npp.2008.125 · External reference
10.1038/clpt.2011.321
10.1038/clpt.2011.321 · External reference
10.1038/clpt.2009.297
10.1038/clpt.2009.297 · External reference
Phenotypic vs. target-based drug discovery for first-in-class medicines
10.1038/clpt.2012.236 · 2013 · External reference
Systems-based discovery advances drug development
10.1038/clpt.2013.21 · 2013 · External reference
10.1016/j.coph.2012.08.005
10.1016/j.coph.2012.08.005 · External reference
10.1371/journal.pmed.1000245
10.1371/journal.pmed.1000245 · External reference
10.1038/nrd3439-c1
10.1038/nrd3439-c1 · External reference
10.1038/483531a
10.1038/483531a · External reference
Deep impact: unintended consequences of journal rank
10.3389/fnhum.2013.00291 · 2013 · External reference
Global and societal implications of the diabetes epidemic
10.1038/414782a · 2001 · External reference
Unresolved reference
2010 · External reference
Association Testing of Previously Reported Variants in a Large Case-Control Meta-analysis of Diabetic Nephropathy
10.2337/db11-0751 · 2012 · External reference
New susceptibility loci associated with kidney disease in type 1 diabetes
10.1371/journal.pgen.1002921 · 2012 · External reference
10.1038/nrg2344
10.1038/nrg2344 · External reference
Bag of Naïve Bayes: biomarker selection and classification from genome-wide SNP data
10.1186/1471-2105-13-s14-s2 · 2012 · External reference
Left ventricular dysfunction with reduced functional cardiac reserve in diabetic and non-diabetic LDL-receptor deficient apolipoprotein B100-only mice
10.1186/1475-2840-10-59 · 2011 · External reference
10.1016/j.ejpain.2005.06.009
10.1016/j.ejpain.2005.06.009 · External reference
Predictive validity of animal pain models? A comparison of the pharmacokinetic-pharmacodynamic relationship for pain drugs in rats and humans
10.1016/j.neuropharm.2008.01.001 · 2008 · External reference
10.1016/j.pain.2012.12.020
10.1016/j.pain.2012.12.020 · External reference
Unresolved reference
2011 · External reference
CXCL5 Mediates UVB Irradiation–Induced
2011 · External reference
10.1002/wsbm.1192
10.1002/wsbm.1192 · External reference
Economic cost of autism in the UK
10.1177/1362361309104246 · 2009 · External reference
Unresolved reference
External reference
10.1038/mp.2012.102
10.1038/mp.2012.102 · External reference
10.1038/npp.2011.185
10.1038/npp.2011.185 · External reference
10.1038/nrd3881
10.1038/nrd3881 · External reference
10.1016/j.conb.2009.06.003
10.1016/j.conb.2009.06.003 · External reference
10.1016/j.neuron.2010.10.004
10.1016/j.neuron.2010.10.004 · External reference
Rate of de novo mutations and the importance of father's age to disease risk
10.1038/nature11396 · 2012 · External reference
10.1016/j.brainres.2010.11.078
10.1016/j.brainres.2010.11.078 · External reference
Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities
10.1101/cshperspect.a009886 · 2012 · External reference
Shared Synaptic Pathophysiology in Syndromic and Nonsyndromic Rodent Models of Autism
10.1126/science.1224159 · 2012 · External reference
Estimates of the cancer incidence and mortality in Europe in 2006
10.1093/annonc/mdl498 · 2007 · External reference
Animal Models of Disease: Pre-clinical Animal Models of Cancer and Their Applications and Utility in Drug Discovery
2013 · External reference
10.1038/nature09495
10.1038/nature09495 · External reference
10.1096/fj.10-157982
10.1096/fj.10-157982 · External reference
Denosumab, a RANK ligand inhibitor, for postmenopausal women with osteoporosis
10.1345/aph.1q543 · 2012 · External reference
10.1126/scitranslmed.3005654
10.1126/scitranslmed.3005654 · External reference
In Silico ADMET Prediction: Recent Advances, Current Challenges and Future Trends
10.2174/15680266113139990033 · 2013 · External reference
Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impurities
10.1016/j.yrtph.2013.05.001 · 2013 · External reference
The eTOX Library of Public Resources for in Silico Toxicity Prediction
10.1002/minf.201200099 · 2013 · External reference
A multiscale simulation system for the prediction of drug-induced cardiotoxicity
10.1021/ci100423z · 2011 · External reference
Application of data mining and visualization techniques for the prediction of drug-induced nausea in man
10.1093/toxsci/kfr334 · 2012 · External reference
Scientific competency questions as the basis for semantically enriched open pharmacological space development
2013 · External reference
European lead factory opens for business
10.1038/nrd3956 · 2013 · External reference
10.1038/nchembio0709-436
10.1038/nchembio0709-436 · External reference
10.1038/nrd3674
10.1038/nrd3674 · External reference
10.1038/nrd2082
10.1038/nrd2082 · External reference
The role of binding kinetics in therapeutically useful drug action
2009 · External reference
The importance of drug-target residence time
2009 · External reference
Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001–2004: mechanisms leading to optimal efficacy and safety
10.2174/156802606776743093 · 2006 · External reference
